Is Aardvark Therapeutics, Inc. Common Stock (AARD) a Buy, Sell, or Hold?
NASDAQ : AARD
Aardvark Therapeutics, Inc. Common Stock
$7.52 USD
$0.29 (4.01%)
- Volume
- 190.61K
- Average Volume
- 263.97K
- Market Capitalization
- $164.57M
- P/E Ratio
- -2.34
- Dividend Yield
- 0.00%
- Price Target
- $4.50
- Year High
- $17.94
- Year Low
- $3.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.06
Company Overview
NASDAQ
Tien-Li Lee
Biotechnology
Healthcare
AARD
40
US
USD
Liquidity Metrics
0.00
8.06
8.06
5.38
0.00
Sales & Valuation
-$
0.00
1.89
-2.67
-2.83
Profitability
-$2.64
-$57.59M
0.00%
0.00%
-61.71%
-70.87%
P/E Metrics
-2.34
0.03
0.03
Analyst Price Target & Rating
$4.50
$6.00
$3.00
2/5
9 Analysts
67.11%
Financial Health Scores
4.17
1/9
$81.98M
$98.59M
$11.6M
-$69.87M
Key Metrics (TTM)
$96.12M
0.00
-1.38
8.06
-61.71%
-85.57%
-44.30%
-39.03%
0 days
Company Executives
| Name | Title |
|---|---|
| Tien-Li Lee | CEO, Secretary & Chairman |
| Zhenhuan Zheng | Chief Research Officer |
| Timothy J. Kieffer | Chief Scientific Officer |
| Justin T. Stege | VP and Head of Project Management & Strategy |
| Nelson Sun | CFO & COO |
| Derrick C. Li | Chief Business Officer |
| Ron Lewis | Vice President & Head of CMC |
| Danny Villeneuve | Chief Commercial Officer |
| Dvorit Samid | Executive Vice President of Medical Affairs |
| Manasi Sinha Jaiman | Chief Medical Officer |
| Christian Zapf | General Counsel |
Poll Results
No votes yet today — be the first to share your view!
About Aardvark Therapeutics, Inc. Common Stock (NASDAQ:AARD) Stock
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surge ... ry or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Hold” by Brokerages
2026-08-04 02:15:45
Shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD - Get Free Report) have earned an average rating of "Hold" from the thirteen analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, four have given a hold recommendation, six have assigned a buy recommendation and one has issued
2026-07-30 13:28:00
SAN FRANCISCO, July 30, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.
2026-07-23 10:05:00
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome (“PWS”) asset.
2026-07-22 16:00:00
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- On May 15, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares significantly decline again – this time, the shares fell $2.16 (-32%). The decline was driven by news that the FDA placed a clinical hold on the company's Prader-Willi Syndrome ("PWS") asset.
2026-06-25 09:00:00
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.
2026-06-19 10:00:00
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire
2026-06-19 09:00:00
SAN FRANCISCO, June 19, 2026 /PRNewswire/ -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Elimination of Reduction Objective ("HERO") trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia (insatiable hunger) in patients with Prader-Willi Syndrome ("PWS"). The development and severe market reaction have prompted national shareholder rights firm Hagens Berman to open an investigation into whether Aardvark may have misled investors in violation of federal securities laws.
2026-06-11 10:00:00
NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Aardvark Therapeutics, Inc. Common Stock (AARD) stock price?
-
Aardvark Therapeutics, Inc. Common Stock(NASDAQ:AARD) stock price is $7.52 in the last trading session. During the trading session, AARD stock reached the peak price of $17.94 while $3.35 was the lowest point it dropped to. The percentage change in AARD stock occurred in the recent session was 4.01% while the dollar amount for the price change in AARD stock was $0.29.
-
AARD's industry and sector of operation?
-
The NASDAQ listed AARD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AARD?
-
Tien-Li Lee | CEO, Secretary & Chairman
Zhenhuan Zheng | Chief Research Officer
Timothy J. Kieffer | Chief Scientific Officer
Justin T. Stege | VP and Head of Project Management & Strategy
Nelson Sun | CFO & COO -
How many employees does AARD have?
-
Number of AARD employees currently stands at 40. AARD operates from 4370 La Jolla Village Drive, San Diego, CA 92122, US.
-
Link for AARD official website?
-
Official Website of AARD is: https://aardvarktherapeutics.com
-
How do I contact AARD?
-
AARD could be contacted at phone #858 225 7696 and can also be accessed through its website. AARD operates from 4370 La Jolla Village Drive, San Diego, CA 92122, US.
-
How many shares of AARD are traded daily?
-
The average number of AARD shares traded daily for last 3 months was 263.97K.
-
What is the market cap of AARD currently?
-
The market value of AARD currently stands at $164.57M with its latest stock price at $7.52